key: cord-0955743-5ijdl5sl
authors: Yang, Katherine
title: What do we know about remdesivir drug interactions?
date: 2020-05-13
journal: Clin Transl Sci
DOI: 10.1111/cts.12815
sha: c8179621b28bbfa721a07fa26342533945aac293
doc_id: 955743
cord_uid: 5ijdl5sl

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐Co‐V‐2) has resulted in a critical need to rapidly develop new pharmacologic interventions and disseminate information. This has led to confusing and conflicting information on drug efficacy. Remdesivir has emerged as a promising treatment for SARS‐Co‐V‐2 infection yet published clinical pharmacology and drug interaction studies are limited. Additional studies of the disposition of remdesivir, its active metabolite (GS‐441524), and its triphosphate metabolite (GS‐443902) are needed.

disseminated on an almost daily basis, often with incomplete or conflicting results and without adequate peer review. Understandably, while the focus of these investigations has centered on therapeutic efficacy, attention should also be paid to the clinical pharmacology and potential for drug-drug interactions which is often lacking published data. For the front-line clinician, this information is vital to providing optimal care for COVID-19 patients with complex underlying medical conditions receiving multiple medications.

Remdesivir (GS-5734), developed by Gilead Sciences, Inc., has recently emerged as a promising new antiviral agent against SARS-CoV-2. Initially developed to combat Ebola, remdesivir has been administered to over 1800 patients worldwide since January, 2020 through clinical trials, individual compassionate use, and expanded access. Published reports of remdesivir have shown mixed efficacy. 2, 3 A case series of 53 hospitalized patients who received remdesivir via the compassionate use program showed an overall mortality of 13%, with higher mortality (18%) in patients who were mechanically ventilated. A randomized, double-blind placebo-controlled trial from China found no benefit of remdesivir compared to placebo.

However, the study was terminated early due to failure to achieve its target enrollment and was, therefore, underpowered to show clinical benefit. Adverse events were similar in both studies, ranging from 60-66% of patient receiving remdesivir (compared with 64% patients receiving placebo). Serious adverse events occurred in 20-23% of patients. Notable adverse events include rash (8%) and abnormal liver function tests (5-23%). More promising preliminary results are emerging from the National Institute of Health Adaptive COVID-19 Clinical Trial (ACTT) which showed a statistically significant decrease in time to recovery, defined as return to normal activity or hospital discharge. The median time to recovery was 11 days for patients treated with remdesivir, compare with 15 days for patients receiving placebo (p<0.001). While not statistically significant, results did suggest a survival benefit with a mortality of 8.0% of patients in the remdesivir group compared to 11.6% of patients in the placebo group (p=0.059). 4 Topline results from the open-label Phase 3 SIMPLE trial showed that patients with severe COVID-19

This article is protected by copyright. All rights reserved. respectively) allowing for once-daily dosing. Remdesivir has wide distribution to most tissues including the kidneys, liver, prostate gland and salivary gland but does not cross the blood-brain barrier. Metabolism is mediated predominantly by hydrolases with 74% and 18% of remdesivir recovered in urine and feces. 10, 11 The majority of remdesivir recovered in urine was metabolite This article is protected by copyright. All rights reserved.

GS-441524; 10% was recovered as remdesivir. It is worth noting that remdesivir is formulated in sulfobutylether--cyclodextrin (SBECD), an excipient to enhance solubility. SBECD has been shown to accumulate in moderate to severe renal dysfunction and, in preclinical studies, has resulted in renal vacuolation. 12 Caution should be exercised when co-administration with other parenteral medications formulated in SBECD (e.g., voriconazole, amiodarone), particularly in patients with creatinine clearance less than 30 ml/min.

To date, there are only limited in vitro transporter and enzyme-mediated drug interaction studies on remdesivir. Remdesivir is a substrate of multiple cytochrome P450 enzymes including CYP2C8, CYP2D6, and CYP3A4, and is also a substrate of the organic anion transporting polypeptide OATP1B1, and P-glycoprotein (P-gp). Remdesivir is also a weak inhibitor of CYP3A4, OATP1B1, OATP1B3, bile acid export pump (BSEP), multidrug resistanceassociated protein 4 (MRP4), and sodium-taurocholate cotransporter protein (NTCP). However, metabolism of remdesivir is believed to be mediated predominantly via hydrolases and not CYP enzymes, as noted above. 11 Due to the high extraction ratio of remdesivir, hepatic clearance is likely driven by hepatic blood flow and not metabolic enzyme activity. This, in addition to the short plasma half-life and need for IV administration that avoids hepatic first pass metabolism, likely results in a low potential for drug-drug interactions with the administered drug. (Table 1) therapies. 13 Listed drugs include remdesivir, lopinavir/ritonavir, chloroquine, hydroxychloroquine, tocilizumab, and favipravir among others. According to the website (accessed 4 May 2020), coadministration of strong CYP3A4 inhibitors such as voriconazole is labeled as "no clinically significant interaction expected." In contrast, co-administration with strong CYP3A4 inducers such as rifampicin can lead to decreased remdesivir levels and it is recommended that "these drugs should not be coadministered." To add to the confusion, three recent published reviews or guidelines of COVID-19 therapeutics resulted in discordant conclusions regarding the significance and clinical management of potential CYP3A4 interactions. McCreary et al correctly noted that the initial ACTT protocol erroneously stated that "remdesivir is a prodrug that is metabolized to its active form as a substrate of CYP3A4" when, in fact, remdesivir is activated to the active metabolite, GG-441524 via plasma carboxylesterases and metabolized by hydrolases. 14 The authors concluded that, while remdesivir is a substrate of multiple CYP isoforms, drug interactions with CYP3A4 inhibitors or inducers were unlikely. This is in contrast to a recent review of COVID-19 pharmacologic therapeutics published in JAMA which states that while "not a significant inducer/inhibitor of CYP enzymes, monitor with strong inducers/inhibitors." 15 On April 21, 2020, the NIH released their own COVID-19 treatment guidelines. 16 In their review, the authors note that while remdesivir is unlikely to be affected by CYP enzymes or P-gp transporters, remdesivir should not be administered with strong CYP or P-gp inducers but may be co-administered with strong CYP inhibitors. The basis for this recommendation is unclear but is clearly aimed at minimizing the potential for subtherapeutic remdesivir levels. While the impact of strong CYP inhibitors, such as voriconazole, is typically limited to the major isoenzyme, CYP3A4, CYP inducers can affect multiple CYP isoenzymes and transporters leading to a larger cumulative decrease in substrate concentration when metabolized and transported via multiple pathways. At present, the contribution of each CYP isoenzyme and transporter to the overall metabolism of remdesivir and its metabolites is This article is protected by copyright. All rights reserved.

unclear. This approach also assumes that increased remdesivir levels, and potentially increased levels of the active metabolite, GS-441524, will not lead to increased toxicity which may or may 

COVID-19 map

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet

Gilead Sciences. Gilead Sciences Statement on Positive Data Emerging From National Insitute of Allergy and Infectious Diseases' Study of Investigational Antiviral Remdesivir for COVID-19

Gilead Sciences. Gilead Announces Results from Phase 3 Trial of Investigational Antiviral Remdesivir in Patients with Severe COVID-19

Food & Drug Administration. Authoriziation for emergency use of remdesivir for the treatment of COVID-19 (letter)

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses

Food & Drug Administration. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Remdesivir (GS-5734)

Review of the Basic and Clinical Pharmacology of Sulfobutylether-β-Cydodextrin (SBECD)

Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis

Pharmacologic Treatments for Coronavirus Disease

Figure 1. Chemical structures of remdesivir (GS-5734) and the nucleoside metabolite, GS-441524. Images sourced from PubChem Database

ted Ar